bacteri
superinfect
contribut
signific
morbid
mortal
associ
influenza
respiratori
viru
infect
robust
anim
model
data
limit
clinic
inform
effect
licens
antivir
agent
treatment
bacteri
complic
influenza
associ
secondari
bacteri
pathogen
fatal
pneumonia
recent
influenza
pandem
highlight
need
new
develop
area
basic
clinic
research
viralbacteri
interact
last
decad
reveal
sever
mechan
underli
synerg
appli
insight
antivir
drug
develop
potenti
exist
improv
outcom
mean
direct
inhibit
viru
autopsi
data
complic
secondari
bacteri
pneumonia
contrast
pandem
kill
million
peopl
worldwid
less
excess
mortal
mani
subsequ
season
epidem
subtypeand
strainspecif
dichotomi
probabl
aris
differ
virul
strain
differ
may
express
interact
host
factor
secondari
bacteri
pathogen
may
quantifi
tradit
measur
virul
replic
effici
diseas
potenti
primari
infect
anim
model
scenario
complic
strainspecif
differ
bacteri
copathogen
influenza
caus
much
morbid
mortal
exampl
promin
secondari
pathogen
pandem
sever
year
thereaft
staphylococcu
aureu
uncommon
caus
secondari
bacteri
infect
sbi
sever
decad
region
clonotyp
methicillinresist
aureu
mrsa
emerg
howev
sever
necrot
staphylococc
pneumonia
one
common
manifest
sever
sbi
thu
specif
virul
factor
express
superinfect
bacteria
must
also
contribut
overal
interact
influenza
virus
effect
factor
diseas
impli
intervent
antivir
therapi
target
could
reduc
mortal
issu
treatment
sbi
must
put
larger
context
acquisit
diagnosi
manag
influenza
secondari
pneumonia
complic
influenza
often
fulmin
present
particularli
aureu
secondari
pathogen
antibiot
therapi
often
unsuccess
case
could
even
contribut
poor
outcom
enhanc
inflamm
bacteri
lysi
ideal
therefor
prevent
sbi
intervent
prior
develop
would
prefer
howev
case
influenza
brought
medic
attent
manag
outpati
set
antivir
treatment
current
recommend
center
diseas
control
cdc
infecti
diseas
societi
america
idsa
present
person
certain
highrisk
medic
condit
healthi
person
hospit
requir
complic
develop
sinc
risk
factor
develop
sbi
follow
influenza
known
less
half
person
develop
secondari
bacteri
pneumonia
requir
hospit
medic
condit
place
highrisk
hospit
influenza
strategi
like
miss
opportun
prevent
sbi
antivir
medic
obviou
way
prevent
sbi
prevent
anteced
viral
infect
entir
anim
model
data
suggest
vaccin
influenza
effect
method
prevent
subsequ
secondari
pneumonia
influenza
vaccin
studi
human
typic
design
appropri
power
assess
effect
sbi
assum
prevent
infect
vaccin
would
also
prevent
complic
sbi
partial
protect
significantli
impact
bacteri
superinfect
neutral
viru
shown
anim
model
necessari
would
crossreact
tcell
base
immun
also
prevent
sbi
question
assess
preclin
human
vaccin
trial
set
altern
strategi
would
target
bacteria
often
complic
influenza
clinic
trial
streptococcu
pneumonia
conjug
vaccin
perform
south
africa
show
prevent
pneumococc
pneumonia
signific
impact
virusassoci
pneumonia
pneumonia
associ
influenza
reduc
associ
parainfluenzavirus
rsv
thu
consid
reason
prevent
sbi
vaccin
influenza
pneumococcu
possibl
haemophilu
influenza
type
b
sinc
vaccin
avail
common
superinfect
bacteria
aureu
group
streptococcu
howev
strategi
impact
part
problem
spring
new
influenza
viru
strain
subtyp
emerg
caus
first
pandem
year
epidemiolog
nascent
pandem
differ
recent
season
influenza
although
hospit
patient
chronic
medic
condit
known
predispos
sever
influenza
young
peopl
disproportion
affect
rel
spare
elderli
popul
elimin
major
sourc
circulatori
respiratori
death
result
less
excess
mortal
previou
epidem
bacteri
superinfect
contributor
hospit
death
often
recogn
earli
report
earli
case
treat
empir
antibiot
invas
assay
detect
copathogen
systemat
done
later
shown
approxim
sever
fatal
case
complic
sbi
patholog
sever
case
character
chiefli
diffus
alveolar
damag
superimpos
find
case
typic
necrot
bacteri
pneumonia
similar
find
autopsi
seri
pandem
role
respiratori
virus
influenza
pathogenesi
sbi
remain
unclear
numer
case
report
case
seri
mostli
children
document
seriou
viralbacteri
coinfect
occur
patient
communityacquir
pneumonia
cap
singl
viru
predomin
studi
cap
children
tabl
rhinoviru
consist
first
incid
studi
diagnost
capabl
detect
use
incid
rhinoviru
well
respiratori
virus
vari
wide
studi
patient
popul
tabl
multipl
virus
includ
respiratori
syncyti
viru
rsv
human
bocaviru
hbov
human
metapneumoviru
hmpv
influenza
b
virus
parainfluenza
virus
piv
also
commonli
detect
studi
occur
around
case
emerg
virus
hmpv
hbov
sever
differ
human
coronavirus
hcov
fill
previous
gap
understand
caus
cap
new
diagnost
becom
avail
one
problem
caus
newer
sensit
assay
pcrbase
techniqu
howev
determin
causal
virus
especi
rhinovirus
bocavirus
found
frequent
case
seri
also
found
asymptomat
subject
subject
coinfect
virus
known
pathogen
anim
particularli
mice
ferret
chinchilla
nonhuman
primat
util
model
sbi
follow
influenza
sinc
time
pandem
review
recent
studi
sbi
mice
use
pneumonia
h
influenza
aureu
base
coinfect
model
deriv
ultim
work
describ
earli
model
mice
infect
intranas
subleth
dose
influenza
viru
follow
day
later
subleth
dose
bacteria
develop
sever
pneumonia
succumb
ill
day
secondari
challeng
bacteri
lung
titer
frequenc
bacteria
access
bloodstream
enhanc
anteced
viral
infect
interestingli
complementari
effect
viru
well
viral
lung
load
increas
day
immedi
follow
bacteri
superinfect
viru
must
given
first
least
day
must
elaps
synergist
effect
observ
explor
time
exposur
mice
ferret
demonstr
mucos
infect
otiti
media
sinus
occur
anim
colon
pneumococcu
later
develop
influenza
howev
invas
diseas
includ
pneumonia
bacteremia
mening
seen
influenza
infect
occur
first
suggest
system
immun
bacteri
pathogen
establish
virusinduc
effect
transit
steril
compart
blunt
signific
implic
epidemiolog
prevent
sbi
suggest
strain
commonli
colon
nasopharynx
suscept
human
influenza
season
necessarili
one
need
target
sinc
viral
infect
increas
suscept
acquisit
new
strain
vaccin
coverag
bacteria
includ
strain
capabl
infect
invad
host
viral
ill
comprehens
longitudin
studi
human
confirm
find
undertaken
numer
studi
mortal
pandem
conclud
bacteria
secondari
invad
primari
agent
diseas
prevail
dogma
sinc
time
explain
phenomenon
airway
damag
provid
foothold
adher
bacteria
damag
epithelium
expos
extracellular
matrix
facilit
develop
pneumonia
concept
support
studi
mice
human
show
physic
associ
bacteria
damag
airway
epithelium
trachea
remov
mice
previous
infect
pathogen
influenza
viru
better
support
adher
bacteria
similar
tissu
uninfect
mice
human
bacteria
found
autopsi
adher
area
tracheobronchi
tree
denud
viral
infect
mechan
inde
major
factor
prime
host
develop
bacteri
superinfect
virul
factor
enhanc
abil
viru
caus
lung
damag
contribut
sbi
virul
influenza
virus
multifactori
trait
gene
product
capabl
contribut
either
independ
interact
viral
protein
thu
antivir
strategi
target
function
viru
result
decreas
viral
fit
diminish
virusassoci
lung
injuri
also
decreas
sbi
chief
mechan
greater
virul
novel
pandem
strain
rel
season
influenza
virus
appear
abil
caus
infect
deep
within
lung
similar
pandem
strain
like
due
lack
glycosyl
hemagglutinin
ha
protein
express
novel
facilit
escap
collagen
lectin
prevent
clearanc
differ
receptor
specif
ha
implic
differ
tropism
within
respiratori
tract
subtyp
avian
virus
anim
novel
strain
share
humanlik
pattern
receptor
specif
common
recent
circul
season
strain
observ
differ
respiratori
tract
local
differ
strain
may
help
explain
differ
support
sbi
virus
enhanc
adher
due
acut
lung
injuri
appeal
mechan
pathogen
pandem
strain
explain
associ
sbi
less
virul
season
strain
inde
sever
mechan
propos
tabl
sialidas
activ
viral
neuraminidas
na
protein
found
correl
support
sbi
mice
viral
sialidas
activ
thought
facilit
access
lower
respiratori
tract
expos
bacteri
receptor
destroy
sialyl
mucin
pneumococc
na
shown
support
transit
nasopharynx
lung
mous
model
util
mutant
defici
sialidas
activ
appeal
model
effect
viral
na
sbi
direct
proof
lack
enzymat
cleavag
substrat
includ
latent
transform
growth
factorbeta
cellular
sialidas
may
provid
offtarget
effect
involv
pathogenesi
addit
recognit
bacteri
sialidas
cleav
sialic
acid
part
avail
carbohydr
sourc
assist
biofilm
format
implic
pathogenesi
viral
namedi
releas
free
sialic
acid
respiratori
tract
may
facilit
transit
nasopharynx
lung
mechan
anoth
receptormedi
mechan
involv
upregul
plateletactiv
factor
paf
receptor
propos
sinc
pneumococcu
util
paf
receptor
cellular
receptor
attach
inflammatori
stimuli
upregul
paf
receptor
express
virusmedi
chang
paf
receptor
distribut
hypothes
facilit
adher
lower
respiratori
tract
howev
studi
knockout
anim
later
reveal
receptor
need
synergist
enhanc
bacteri
superinfect
viru
previou
studi
attribut
role
paf
receptor
like
confound
use
strain
caus
bacteremia
later
shown
main
role
paf
receptor
pneumococc
pathogenesi
enhanc
transit
across
endotheli
cell
lung
blood
blood
cerebrospin
fluid
recent
investig
mechan
viralbacteri
synerg
center
around
modul
host
immun
respons
viru
influenza
commonli
associ
leukocytosi
also
caus
lymphopenia
neutropenia
human
cytokin
storm
gener
leukopenia
commonli
associ
human
infect
highli
pathogen
avian
influenza
virus
subtyp
interplay
viral
host
factor
immun
respons
poorli
understood
present
viral
strainspecif
factor
host
variat
account
mark
differ
seen
individu
studi
puzzl
unravel
earli
infect
influenza
viru
cytotoxin
drive
inflammatori
respons
caus
infiltr
neutrophil
macrophag
lung
result
acut
lung
injuri
mous
model
respond
cell
may
function
impair
viru
diminish
capac
host
clear
bacteri
copathogen
simultan
caus
ali
function
deficit
neutrophil
macrophag
natur
killer
cell
link
wors
outcom
sbi
anim
model
numer
proinflammatori
cytokin
chemokin
upregul
lung
secondari
bacteri
pneumonia
result
interact
multipl
viral
bacteri
virul
factor
includ
mediat
effect
seem
particularli
import
pandem
highli
virul
virus
shown
contribut
sbi
associ
recent
season
strain
express
function
form
cytotoxin
late
infect
resolut
primari
viral
infect
desensit
innat
respons
increas
incid
sbi
mice
effect
neg
regul
inflamm
resolut
influenza
may
prevent
adequ
host
respons
secondari
pathogen
releas
interferongamma
tcell
may
also
contribut
diminish
capac
alveolar
macrophag
clear
bacteria
lung
biphas
respons
inflamm
promin
earli
antiinflammatori
process
domin
late
impli
time
onset
sbi
may
major
influenc
mechan
oper
promin
role
host
process
impli
cellular
target
pharmaceut
intervent
exist
specif
antiinflammatori
agent
target
pathway
util
viral
bacteri
cytotoxin
agonist
revers
effect
influenza
viru
innat
respons
investig
speci
strain
superinfect
bacteria
also
affect
biphas
host
respons
influenza
virus
anim
model
clear
differ
bacteri
strain
contribut
sbi
differ
pattern
diseas
addit
signific
differ
mous
model
pneumonia
aureu
suggest
pathogenesi
mechan
use
interact
influenza
viru
differ
propos
pandem
three
distinct
set
outcom
could
recogn
among
develop
bacteri
pneumonia
classif
scheme
divid
patient
primari
influenza
viru
pneumonia
late
bacteri
pneumonia
present
resolut
primari
influenza
concomit
viralbacteri
pneumonia
case
concomit
viralbacteri
pneumonia
group
tend
fulmin
often
fatal
late
bacteri
pneumonia
aureu
commonli
found
combin
group
mechan
involv
inflamm
predomin
abil
aureu
particularli
clonotyp
express
multipl
cytoxin
like
contribut
phenotyp
pneumococcu
predomin
caus
sbi
patient
develop
sbi
late
phase
presum
inabl
clear
secondari
pathogen
due
antiinflammatori
milieu
respons
mechan
underli
potenti
interact
respiratori
virus
bacteria
less
clear
show
parallel
mechan
propos
influenza
viru
sever
medic
import
virus
shown
increas
bacteri
adher
vitro
ex
vivo
model
rsv
piv
upregul
receptor
common
respiratori
bacteria
sialidas
activ
sendai
viru
piv
hemagglutininneuraminidas
hn
protein
enhanc
sbi
mous
model
alter
innat
immun
includ
disrupt
mucos
barrier
dysregul
defensin
implic
anim
model
coinfect
respiratori
virus
bacteria
given
strong
associ
bacteri
diseas
anteced
viral
infect
understand
interest
determin
whether
prevent
treatment
viru
elimin
amelior
sbi
two
class
antivir
drug
current
approv
use
patient
influenza
addit
numer
antivir
drug
direct
multipl
target
influenza
viru
life
cycl
progress
preclin
earli
clinic
stage
review
fewer
candid
exist
respiratori
virus
none
far
reach
approv
stage
unlik
antibiot
elimin
greatli
reduc
pathogen
burden
exist
influenza
antivir
drug
serv
halt
progress
diseas
prevent
new
host
cell
infect
intervent
administ
earli
enough
clinic
cours
may
alter
tempo
infect
allow
normal
immun
clearanc
mechan
gain
upper
hand
earlier
treatment
work
better
case
infect
yet
widespread
thu
major
effect
treatment
symptom
reduct
rapid
recoveri
immedi
clinic
cure
context
prevent
sbi
continu
presenc
viru
ongo
host
respons
suggest
mani
mechan
discuss
may
remain
oper
despit
treatment
howev
might
also
expect
continuum
treatment
effect
exist
wherebi
decreas
viru
replic
result
decreas
ali
thu
presum
diminish
host
respons
provid
clinic
benefit
preclin
work
mous
model
demonstr
prophylaxi
earli
treatment
nai
decreas
viral
load
weight
loss
significantli
reduc
sbi
antivir
use
decreas
incid
sbi
lengthen
interv
exposur
bacteria
develop
diseas
slow
progress
pneumonia
develop
facilit
antibiot
treatment
superinfect
similar
effect
seen
paramyxoviru
model
util
specif
inhibitor
piv
hn
howev
influenza
viru
naspecif
effect
independ
effect
viral
replic
also
seen
delay
treatment
day
initi
viral
infect
also
significantli
decreas
sbi
sinc
viral
lung
load
virusinduc
clinic
ill
differ
group
delay
therarpi
offtarget
effect
drug
inhibit
secondari
effect
viral
na
substrat
unrel
viral
life
cycl
must
involv
strengthen
associ
second
studi
mice
reveal
level
na
activ
histor
recombin
virus
correl
support
sbi
impli
nai
treatment
influenza
might
differ
effect
sbi
depend
viral
strain
target
although
convinc
anim
data
suggest
nai
effect
sbi
mechan
remain
unclear
inhibit
namedi
desialyl
potenti
receptor
bacteri
adher
contribut
effect
hypothes
date
shown
indirectli
inhibit
adher
vitro
prevent
pneumonia
vivo
use
recombin
na
mice
effect
similar
na
context
full
viru
issu
specif
enzym
na
act
target
abil
influenza
viru
na
cleav
activ
latent
suggest
pleiotrop
effect
influenza
virus
immun
wound
heal
possibl
inhibit
effect
prevent
cleavag
potenti
substrat
enzym
could
influenc
multipl
pathway
import
immun
respons
hand
nai
may
offtarget
effect
well
inhibit
cellular
sialidas
one
cellular
enzym
involv
tolllik
receptor
tlr
signal
activ
sinc
involv
host
respons
bacteri
pathogen
includ
pneumonia
acut
lung
injuri
influenza
virus
induct
sbi
interact
nai
could
signific
downstream
effect
like
base
vaccin
effect
improv
efficaci
earli
vs
late
treatment
oseltamivir
direct
inhibit
viral
replic
viralinduc
lung
damag
prevent
amelior
sbi
complic
influenza
sbi
systemat
assess
preclin
develop
novel
antivir
drug
human
data
efficaci
exist
antivir
agent
sbi
limit
present
incid
low
gener
popul
develop
countri
studi
design
specif
assess
outcom
would
extrem
larg
wellpow
use
highrisk
group
could
reduc
sampl
size
also
present
challeng
studi
subject
like
see
high
rate
sbi
frail
elderli
would
confound
use
influenza
pneumococc
vaccin
could
ethic
withheld
studi
particip
nonetheless
data
avail
exist
clinic
studi
random
doubleblind
placebocontrol
trial
oseltamivir
use
children
treatment
influenza
result
reduct
diagnos
otiti
media
lower
prescript
rate
antibiot
placebo
group
reanalysi
pool
data
sever
prospect
clinic
trial
nai
antivir
use
adult
reduc
incid
lower
respiratori
tract
infect
antibiot
use
metaanalysi
similar
data
also
conclud
antivir
effect
prevent
sbi
caution
group
risk
outcom
typic
exclud
particip
lack
coordin
studi
design
unavail
data
trial
led
critic
conclus
drawn
analys
point
need
random
clinic
trial
specif
design
endpoint
mind
retrospect
review
outcom
deriv
insur
claim
databas
found
prescript
oseltamivir
adult
children
influenza
result
reduct
risk
pneumonia
children
otiti
media
hospit
similar
analysi
children
highrisk
medic
condit
primarili
chronic
lung
diseas
show
treatment
oseltamivir
associ
reduct
otiti
media
respiratori
ill
pneumonia
hospit
impact
pneumonia
analysi
specif
risk
group
adult
diabet
show
similar
outcom
reduct
risk
respiratori
ill
reduct
risk
hospit
signific
effect
otiti
media
pneumonia
diagnos
trial
deriv
code
specif
attribut
bacteri
diseas
distinct
sever
viral
ill
could
made
sinc
widespread
prophylaxi
treatment
nai
undertaken
recent
pandem
may
possibl
analyz
treat
popul
effect
sbi
without
goldstandard
clinic
trial
howev
may
need
continu
reli
preclin
data
anim
model
expert
opinion
time
abil
nai
prevent
sbi
independ
effect
viral
load
suggest
interfer
viral
target
vaccin
small
molecul
therapi
monoclon
antibodi
sirna
approach
might
effect
would
anticip
base
direct
viral
suppress
specif
blockad
proinflammatori
effect
might
diminish
sever
highli
pathogen
influenza
virus
reduc
sbi
howev
knowledg
bind
partner
mechan
action
need
becom
realist
goal
complementari
strategi
target
bacteri
toxin
shown
synergist
interact
influenza
virus
enhanc
diseas
could
also
explor
inhibit
interferon
antagonist
nonstructur
protein
allow
enhanc
clearanc
viru
could
prevent
sever
downstream
effect
viru
host
immun
like
increas
suscept
bacteria
use
collectinlik
molecul
recogn
ha
glycan
ha
might
diminish
diffus
alveolar
damag
caus
virus
access
lower
respiratori
tract
secondari
effect
sbi
exogen
surfact
therapi
contain
protein
success
adult
patient
acut
respiratori
distress
syndrom
ard
evalu
specif
treatment
influenza
sbi
target
host
pathway
import
either
virul
influenza
virus
interact
secondari
bacteri
pathogen
consid
altern
potenti
complementari
strategi
target
viru
clear
basic
research
influenza
viru
pathogenesi
interact
bacteria
need
broader
strategi
immunomodul
reduc
inflammatori
respons
sbi
propos
tabl
although
argument
current
rest
biolog
plausibl
yet
support
either
anim
model
clinic
data
human
infer
studi
design
target
sepsi
ard
sever
influenza
made
system
steroid
use
quit
frequent
pandem
publish
studi
sever
ill
patient
treat
corticosteroid
howev
clinic
benefit
steroid
shown
ard
specif
influenza
antibodi
therapi
includ
current
avail
intraven
immun
globulin
ivig
prepar
hyperimmun
sera
recov
vaccin
individu
specif
monoclon
antibodi
therapi
propos
potenti
treatment
sever
influenza
specif
monoclon
approach
would
expect
antivir
effect
ivig
hyperimmun
sera
might
also
immunomodulatori
effect
data
mous
model
support
efficaci
three
approach
primari
influenza
although
data
avail
model
sbi
limit
clinic
data
human
support
approach
conceptu
primarili
uncontrol
studi
treatment
pandem
influenza
data
anim
model
suggest
target
specif
pathway
involv
inflamm
might
better
success
propos
drug
immunomodul
sever
influenza
includ
statin
inhibit
cholesterol
biosynthesi
pathway
enzym
agonist
peroxisom
proliferatoractiv
receptor
includ
fibrat
thiozolidinedion
cyclooxygenas
pathway
inhibitor
antioxid
nacetyllcystein
shown
benefit
influenza
mice
thialidinedion
ciglitazon
also
shown
reduc
inflammatori
respons
pneumonia
mice
suggest
might
use
dual
infect
potenti
candid
statin
studi
human
thu
far
disappoint
result
cohort
studi
person
prescrib
statin
cholesterollow
properti
shown
obviou
clinic
benefit
influenza
morbid
altern
medicin
deriv
plant
anim
sourc
also
propos
potenti
therapeut
base
anim
model
data
tradit
use
antiinflammatori
agent
review
agent
reduc
inflammatori
respons
influenza
consequ
without
impair
immun
clearanc
viru
possibl
sbi
would
impact
well
complementari
approach
treatment
sbi
might
alter
antibiot
use
treatment
bacteri
superinfect
standard
cellwal
activ
agent
current
clinic
use
rapidli
lyse
bacteria
releas
proinflammatori
compon
contain
pathogenassoci
molecular
pattern
pamp
recogn
innat
immun
system
trigger
inflammatori
burst
use
altern
antibiot
immedi
lyse
bacteria
might
provid
clinic
cure
without
contribut
inflammatori
milieu
theori
test
mous
model
secondari
bacteri
pneumonia
mice
pneumococc
pneumonia
follow
influenza
clinic
cure
use
protein
synthesi
inhibitor
clindamycin
macrolid
azithromycin
surviv
treat
cell
wall
activ
agent
ampicillin
azithromycin
antiinflammatori
activ
independ
mechan
antibacteri
action
perform
best
model
although
strategi
test
combin
viralbacteri
pneumonia
human
indirectli
assess
complic
pneumococc
pneumonia
two
retrospect
studi
one
prospect
multicent
trial
demonstr
combin
therapi
macrolid
betalactam
result
signific
reduct
mortal
compar
betalactam
therapi
alon
adult
bacterem
pneumonia
pneumonia
recent
demonstr
macrolid
immunomodulatori
effect
children
influenza
suggest
benefici
effect
beyond
antibacteri
activ
may
possibl
antivir
drug
develop
respiratori
virus
surprisingli
difficult
task
agent
made
market
pauciti
candid
pipelin
sinc
initi
licens
nai
howev
promis
new
agent
develop
much
recent
progress
spur
factor
need
prepar
sever
influenza
pandem
expand
understand
viral
pathogenesi
accompani
increas
recognit
much
morbid
mortal
associ
respiratori
viru
infect
mediat
sbi
improv
understand
pathogenesi
interact
lead
measur
prevent
interrupt
synerg
specif
factor
viru
superinfect
bacteria
host
could
target
alon
combin
approach
final
need
improv
clinic
epidemiolog
data
secondari
infect
clinic
trial
viral
vaccin
antivir
drug
includ
bacteri
complic
endpoint
allow
true
datadriven
guidanc
treatment
sbi
develop
immunomodulatori
agent
may
use
adjunct
treatment
secondari
bacteri
infect
type
class
agent
exampl
propos
target
mechan
action
corticosteroid
dexamethason
methylprednisolon
pleiotrop
antiinflammatori
effect
antibodybas
therapi
ivig
hyperimmun
serum
monoclon
antibodi
specif
neutral
viru
nonspecif
bind
inflammatori
intermedi
statin
simvastatin
pravastatin
atorvastatin
coenzym
reductas
inhibitor
broad
antiinflammatori
effect
ppar
agonist
gemfibrozil
piaglitazon
ciglitazon
prevent
excess
releas
proinflammatori
cytokin
cox
inhibitor
celecoxib
mesalazin
decreas
proinflammatori
cytokin
eicosanoid
antioxid
nacetyllcystein
decreas
product
proinflammatori
mediat
herb
extract
glycyrrhizin
angelica
sinensi
salvia
miltiorrhiza
decreas
product
proinflammatori
cytokin
antiinflammatori
antibiot
azithromycin
clarithromycin
elimin
superinfect
bacteria
without
lysi
potenti
addit
antiinflammatori
effect
unknown
mechan
